In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback